QIA Stock Analysis: QIAGEN | XETRA
Diagnostics & Research | XETRA, Germany | Market Cap: 7.028m EUR | 12M Return: -12.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.7M
EPS Trend: -2.0%
Qual. Beats: -1
Rev. Trend: 86.6%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
QIAGEN N.V. is a Netherlands-based life sciences tools company that provides sample-to-insight solutions, converting biological materials into molecular insights for customers worldwide. Its product portfolio spans sample preparation consumables (nucleic acid stabilization and purification kits), instruments for purification and quality control, assay kits for tuberculosis testing, transplant monitoring, viral load detection, prenatal screening, sexually transmitted infections, and HPV, as well as research PCR consumables, next-generation sequencing (NGS) library prep and gene panels, and DNA methylation analysis. The company also sells bioinformatics software and offers its products via a software-as-a-service model, serving the molecular diagnostics and life sciences sectors. Founded in 1984, QIAGEN is headquartered in Venlo, the Netherlands, and trades on the XETRA exchange under the ticker QIA.
Unlike pharmaceutical or therapeutics developers, QIAGEN operates as a tools and consumables provider to the broader life sciences and clinical diagnostics value chain, supplying the reagents, instruments, and software that laboratories rely on for genetic and molecular analysis. A significant portion of its revenue is generated through recurring sales of consumables tied to its installed base of instruments, which is a common commercial model among molecular biology tools companies.
- Bio-Rad merger expands molecular diagnostics scale and platform breadth
- QIAstat-Dx respiratory panel adoption drives seasonal testing revenue growth
- QuantiFERON-TB Plus volume anchors immune response segment margins
| Net Income: 401.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.95 > 1.0 |
| NWC/Revenue: 50.41% < 20% (prev 61.21%; Δ -10.80% < -1%) |
| CFO/TA 0.11 > 3% & CFO 614.8m > Net Income 401.9m |
| Net Debt (1.22b) to EBITDA (797.6m): 1.53 < 3 |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (208.9m) vs 12m ago -5.11% < -2% |
| Gross Margin: 61.77% > 18% (prev 50.77%; Δ 11.00% > 0.5%) |
| Asset Turnover: 37.10% > 50% (prev 36.12%; Δ 0.98% > 0%) |
| Interest Coverage Ratio: 13.89 > 6 (EBIT TTM 513.5m / Interest Expense TTM 37.0m) |
| A: 0.18 (Total Current Assets 1.53b - Total Current Liabilities 477.3m) / Total Assets 5.76b |
| B: 0.48 (Retained Earnings 2.79b / Total Assets 5.76b) |
| C: 0.09 (EBIT TTM 513.5m / Avg Total Assets 5.65b) |
| D: 1.36 (Book Value of Equity 3.32b / Total Liabilities 2.44b) |
| Altman-Z'' = 4.82 = AA |
| DSRI: 1.15 (Receivables 409.8m/340.7m, Revenue 2.10b/2.00b) |
| GMI: 0.82 (GM 50.77% / 61.77%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 1.05 (Revenue 2.10b / 2.00b) |
| TATA: -0.04 (NI 401.9m - CFO 614.8m) / TA 5.76b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at EUR 36.41 with a total of 801,902 shares traded. Over the past week, the price has changed by +6.09%, over one month by +13.85%, over three months by +4.82% and over the past year by -12.35%.
Current recommended Stop Loss: 34.80 (which is 4.4% or 1.4 ATR below the current price).
QIAGEN has no consensus analysts rating.
Market Cap USD = 8.03b (7.03b EUR * 1.1431 EUR.USD)
P/E Trailing = 19.811
P/E Forward = 12.5313
P/S = 3.4025
P/B = 2.466
P/EG = 1.0021
Revenue TTM = 2.10b USD
EBIT TTM = 513.5m USD
EBITDA TTM = 797.6m USD
Long Term Debt = 1.65b USD (from longTermDebt, last quarter)
Short Term Debt = 57.7m USD (from shortTermDebt, last fiscal year)
Debt = 1.86b USD (corrected: LT Debt 1.65b + ST Debt 57.7m) + Leases 157.9m
Net Debt = 1.22b USD (calculated: Debt 1.86b - CCE 643.8m)
Enterprise Value = 9.25b USD (8.03b + Debt 1.86b - CCE 643.8m)
Interest Coverage Ratio = 13.89 (Ebit TTM 513.5m / Interest Expense TTM 37.0m)
EV/FCF = 22.55x (Enterprise Value 9.25b / FCF TTM 410.3m)
FCF Yield = 4.44% (FCF TTM 410.3m / Enterprise Value 9.25b)
FCF Margin = 19.57% (FCF TTM 410.3m / Revenue TTM 2.10b)
Net Margin = 19.17% (Net Income TTM 401.9m / Revenue TTM 2.10b)
Gross Margin = 61.77% ((Revenue TTM 2.10b - Cost of Revenue TTM 801.8m) / Revenue TTM)
Gross Margin QoQ = 62.53% (prev 59.77%)
Tobins Q-Ratio = 1.61 (Enterprise Value 9.25b / Total Assets 5.76b)
Interest Expense / Debt = 1.99% (Interest Expense 37.0m / Debt 1.86b)
Taxrate = 11.90% (54.3m / 456.2m)
NOPAT = 452.3m (EBIT 513.5m * (1 - 11.90%))
Current Ratio = 3.21 (Total Current Assets 1.53b / Total Current Liabilities 477.3m)
Debt / Equity = 0.56 (Debt 1.86b / totalStockholderEquity, last quarter 3.32b)
Debt / EBITDA = 1.53 (Net Debt 1.22b / EBITDA 797.6m)
Debt / FCF = 2.97 (Net Debt 1.22b / FCF TTM 410.3m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 401.9m / Total Assets 5.76b)
RoE = 11.28% (Net Income TTM 401.9m / Total Stockholder Equity 3.56b)
RoCE = 9.86% (EBIT 513.5m / Capital Employed (Equity 3.56b + L.T.Debt 1.65b))
RoIC = 8.64% (NOPAT 452.3m / Invested Capital 5.24b)
WACC = 6.22% (E(8.03b)/V(9.90b) * Re(7.26%) + D(1.86b)/V(9.90b) * Rd(1.99%) * (1-Tc(0.12)))
Discount Rate = 7.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -1.79%
[DCF] Terminal Value 73.10% ; FCFF base≈447.4m ; Y1≈392.4m ; Y5≈317.0m
[DCF] Fair Price = 18.76 (EV 5.09b - Net Debt 1.22b = Equity 3.87b / Shares 206.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -2.05 | EPS CAGR: -0.10% | SUE: -4.0 | # QB: -1
Revenue Correlation: 86.60 | Revenue CAGR: 2.79% | SUE: -1.66 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.51 | Chg30d=-2.49% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.52 | Chg30d=-5.42% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=+0.01% | Revisions=+25% | GrowthEPS=+3.3% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=2.25 | Chg30d=-0.03% | Revisions=+50% | GrowthEPS=+8.1% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: +22% (up=4, down=2)